The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Glucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same?
Abstract
Summary: Glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are an important class of drugs with a well‐established efficacy and safety profile in patients with type 2 diabetes mellitus. Agents in this class are derived from either exendin‐4 (a compound present in Gila monster venom) or modifications of human GLP‐1 active fragment. Differences among these drugs in duration of action (ie, short‐acting vs long‐acting), effects on glycaemic control and weight loss, immunogenicity, tolerability profiles, and administration routes offer physicians several options when selecting the most appropriate agent for individual patients. Patient preference is also an important consideration. The aim of this review is to discuss the differences between and similarities of GLP‐1 RAs currently approved for clinical use, focusing particularly on the properties characterising the single short‐acting and long‐acting GLP‐1 RAs rather than on their individual efficacy and safety profiles. The primary pharmacodynamic difference between short‐acting (ie, exenatide twice daily and lixisenatide) and long‐acting (ie, albiglutide, dulaglutide, exenatide once weekly, liraglutide, and semaglutide) GLP‐1 RAs is that short‐acting agents primarily delay gastric emptying (lowering postprandial glucose) and long‐acting agents affect both fasting glucose (via enhanced glucose‐dependent insulin secretion and reduced glucagon secretion in the fasting state) and postprandial glucose (via enhanced postprandial insulin secretion and inhibition of glucagon secretion). Other advantages of long‐acting GLP‐1 RAs include smaller fluctuations in plasma drug concentrations, improved gastrointestinal tolerability profiles, and simpler, more convenient administration schedules (once daily for liraglutide and once weekly for albiglutide, dulaglutide, the long‐acting exenatide formulation, and semaglutide), which might improve treatment adherence and persistence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“8 mg than in those receiving placebo.(92) In the SUSTAIN‐6 trial, semaglutide was associated with a significant reduction in the first occurrence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke among patients with T2DM with a high cardiovascular risk.”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 1×
“com when approximately 3 months of initial treatment with metformin alone has failed to reduce glycosylated haemoglobin (HbA1c) to target levels in patients with type 2 diabetes mellitus (T2DM).(1) Glucagon‐like peptide‐1 RAs can also be added to multiple oral anti‐diabetic drugs (OADs); use in combination with insuli…”
BackgroundLixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 15×
“In general, GLP‐1 RAs can be categorised as either “short‐acting” (having short‐lived receptor activation, eg, exenatide twice daily and lixisenatide) or “long‐acting” (producing continuous activation of the GLP‐1 receptor at recommended dosages, eg, albiglutide, dulaglutide, exenatide once weekly, liraglutide, and se…”
BackgroundInfluentialKendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129 · cited 1×
“Other reported benefits of GLP‐1 RAs in patients with T2DM include reductions in systolic and diastolic blood pressure and improvements in lipid profiles.(14,15,32,36,37,42,45-49,52,53,58-63,65,71,81) Modest improvements in nonclinical parameters such as markers of beta‐cell function have also been reported.”
Background
Cited by
GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
Ma, X., Liu, Z., Ilyas, I., Little, P. J., Kamato, D., Sahebka, A., Chen, Z., Luo, S., Zheng, X., Weng, J., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59965 · Cited by 299
Ryan, D. H., Lingvay, I., Colhoun, H. M., Deanfield, J., Emerson, S. S., Kahn, S. E., Kushner, R. F., Marso, S., Plutzky, J., Brown-Frandsen, K., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.07.008 · Cited by 249
“Several agents in this class have been approved to date for the treatment of type 2 diabetes: exenatide, lixisenatide, liraglutide, dulaglutide, albiglutide, exenatide extended release, and semaglutide.(31) Furthermore, liraglutide is also approved for themedical treatment of obesity, and semaglutide is currently unde…”
BackgroundEffects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity
Maselli, D. B., & Camilleri, M. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_496 · Cited by 248
Urva, S., Coskun, T., Loghin, C., Cui, X., Beebe, E., O'Farrell, L., Briere, D. A., Benson, C., Nauck, M. A., & Haupt, A. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14110 · Cited by 143
Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism
Bu, T., Sun, Z., Pan, Y., Deng, X., & Yuan, G. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0277 · Cited by 131
Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective
De Block, C., Bailey, C., Wysham, C., Hemmingway, A., Allen, S. E., & Peleshok, J. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14831 · Cited by 121
Hu, W., Song, R., Cheng, R., Liu, C., Guo, R., Tang, W., Zhang, J., Zhao, Q., Li, X., & Liu, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.927859 · Cited by 127
“However, individual tolerability and safety to GLP-1RA may vary due to differences in molecular structures (77).”
BackgroundCao, C., Yang, S., & Zhou, Z. (2019) · Endocrine · doi:10.1007/s12020-019-02055-z · Cited by 99
Alzheimer’s disease as type 3 diabetes: understanding the link and implications
Kciuk, M., Kruczkowska, W., Gałęziewska, J., Wanke, K., Kałuzińska-Kołat, Ż., Aleksandrowicz, M., & Kontek, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252211955 · Cited by 98
“Growing interest has been directed toward the potential use of glucagon-like peptide-1 (GLP-1) receptor agonists in AD, based on their success in treating T2DM [254,255] and their effects on neural health.”
Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
Lyseng-Williamson, K. A. (2019) · Clinical Drug Investigation · doi:10.1007/s40261-019-00826-0 · Cited by 87
Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance
Almandoz, J. P., Lingvay, I., Morales, J., & Campos, C. (2020) · Clinical Diabetes · doi:10.2337/cd19-0100 · Cited by 74
The Impact of GLP1 Agonists on Bone Metabolism: A Systematic Review
Daniilopoulou, I., Vlachou, E., Lambrou, G. I., Ntikoudi, A., Dokoutsidou, E., Fasoi, G., Govina, O., Kavga, A., & Tsartsalis, A. N. (2022) · Medicina · doi:10.3390/medicina58020224 · Cited by 74
Recent advances in understanding the role of glucagon-like peptide 1
Reed, J., Bain, S., & Kanamarlapudi, V. (2020) · F1000Research · doi:10.12688/f1000research.20602.1 · Cited by 66
Pratt, E., Ma, X., Liu, R., Robins, D., Coskun, T., Sloop, K. W., Haupt, A., & Benson, C. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15150 · Cited by 60
“that allow once-weekly injection, such as dulaglutide and semaglutide.(6) Currently, the only approved oral GLP-1RA is a specialized formulation of semaglutide that is only indicated for patients with T2D (sold as Rybelsus); however, this oral formulation of semaglutide (14 mg) does not match the greater efficacy of i…”
BackgroundGoldberg, A., Graca, S., Liu, J., Rao, V., Witchel, S. F., Pena, A., Li, R., Mousa, A., Tay, C. T., Pattuwage, L., et al. (2024) · Obesity Reviews · doi:10.1111/obr.13704 · Cited by 59
Alcohol-mediated behaviours and the gut-brain axis; with focus on glucagon-like peptide-1
Jerlhag, E. (2020) · Brain Research · doi:10.1016/j.brainres.2019.146562 · Cited by 53
“In a clinical setting liraglutide can be administered once daily (for review see (Gentilella et al., 2019)).”
InfluentialElsanhoury, A., Nelki, V., Kelle, S., Van Linthout, S., & Tschöpe, C. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.720690 · Cited by 51
Knerr, P. J., Mowery, S. A., Finan, B., Perez-Tilve, D., Tschöp, M. H., & DiMarchi, R. D. (2020) · Peptides · doi:10.1016/j.peptides.2019.170225 · Cited by 49
Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials
Rosenstock, J., Vázquez, L., Del Prato, S., Franco, D. R., Weerakkody, G., Dai, B., Landó, L. F., Bergman, B. K., & Rodríguez, A. (2023) · Diabetes Care · doi:10.2337/dc23-0872 · Cited by 45
Camilleri, M., & Lupianez-Merly, C. (2024) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002519 · Cited by 41
Protein- and Calcium-Mediated GLP-1 Secretion: A Narrative Review
Watkins, J. D., Koumanov, F., & Gonzalez, J. T. (2021) · Advances in Nutrition · doi:10.1093/advances/nmab078 · Cited by 40
Quast, D. R., Nauck, M. A., Schenker, N., Menge, B. A., Kapitza, C., & Meier, J. J. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14477 · Cited by 39
Shuai, Y., Yang, G., Zhang, Q., Li, W., Luo, Y., Ma, J., Chen, D., Yang, J., Wang, X., Hu, J., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14198 · Cited by 35
From hyperglycemia to intervertebral disc damage: exploring diabetic-induced disc degeneration
Li, S., Du, J., Huang, Y., Gao, S., Zhao, Z., Chang, Z., Zhang, X., & He, B. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1355503 · Cited by 32
GLP-1 Receptor Agonists Induce Growth Hormone Secretion in Healthy Volunteers
Heinla, K., Vasar, E., Reppo, I., Sedman, T., & Volke, V. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01381-w · Cited by 30
Gentinetta, S., Sottotetti, F., Manuelli, M., & Cena, H. (2024) · Diabetes, Metabolic Syndrome and Obesity · doi:10.2147/dmso.s494919 · Cited by 32
“14 Human GLP-1 analogues are modified versions of the GLP-1 peptide, 15,16 available in several sizes and structures, influencing their mechanism of action and half-life.”
Langmach Wegeberg, A., Hansen, C. S., Farmer, A. D., Karmisholt, J. S., Drewes, A. M., Jakobsen, P. E., Brock, B., & Brock, C. (2020) · United European Gastroenterology Journal · doi:10.1177/2050640620925968 · Cited by 28
Zhu, C., Li, H., Kong, X., Wang, Y., Sun, T., & Wang, F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.819470 · Cited by 26
Exendin-4 for Parkinson's disease
Esparza-Salazar, F. D. J., Lezama-Toledo, A. R., Rivera-Monroy, G., & Borlongan, C. V. (2021) · Brain Circulation · doi:10.4103/bc.bc_21_21 · Cited by 22
“42 Brain Circulation ‐ Volume 7, Issue 1, January‐March 2021 glucagon‐like peptide‐1 (GLP‐1) as well as exendin‐4, a long‐acting GLP‐1 receptor (GLP‐1R) agonist which has been approved for the treatment of type 2 diabetes mellitus,[10,11] have a protective effect against tyrosine hydroxylase immunoreactivity (THir) in…”
BackgroundDong, Y., Wu, J., Chang, C., Lin, J., Wu, L., & Toh, S. (2022) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2688 · Cited by 16
Osumili, B., Fan, L., Paik, J. S., Pantalone, K. M., Ranta, K., Sapin, H., & Tofé, S. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111717 · Cited by 8
Metadata
- Authors
- Gentilella, R., Pechtner, V., Corcos, A., & Consoli, A.
- Venue
- Diabetes/Metabolism Research and Reviews
- Publisher
- Wiley
- Published
- 2018-10-04
- Volume
- 35
- Issue
- 1
- Pages
- e3070-e3070
- ISSN
- 1520-7552 (ISSN-L)
- 1520-7560
- OpenAlex
- W2889521172
- Cited by
- 227
- References
- 54
- FWCI
- 17.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.